JKT:HEAL
PT Medikaloka Hermina Tbk · JKT · Healthcare · IDR · FY for 2025
Figures on this page computed 2026-11-07 13:58 UTC
Last close
n/aIDR
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
16.9xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
6.0%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
-8.6%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
2.1%Dividend yield
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
Growth is the furthest below its sector's middle: 0.34 against 0.47 on the market's range.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales1.54x
Its own average over 10 years, 4.64T.
- Profit1.08x
Its own average over 10 years, 397.09B.
- Free cash flow2.30x
Its own average over 10 years, -265.62B.
- Debt1.80x
Its own average over 10 years, 1.79T.
- Pricen/a
Its own average over 0 years. Market data
Free cash flow is furthest from its own average, at 2.30 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-12-31 | 100.0 | 100.0 | 100.0 |
| 2017-12-31 | 119.9 | 157.3 | 87.8 |
| 2018-12-31 | 136.9 | 200.6 | 97.5 |
| 2019-12-31 | 162.5 | 554.7 | 104.8 |
| 2020-12-31 | 197.7 | 1,041.4 | 103.4 |
| 2021-12-31 | 260.5 | 1,606.5 | 103.6 |
| 2022-12-31 | 219.4 | 481.6 | 100.9 |
| 2023-12-31 | 258.9 | 705.4 | 102.2 |
| 2024-12-31 | 301.5 | 864.5 | 103.1 |
| 2025-12-31 | 319.3 | 692.9 | 105.1 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- IDR
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- IDR
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- IDR
Figures behind the shape
Growth
10.1%faster is higher, placed against 4,950 companies as of 2026-11-06
Five-year revenue growth rate10.1%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
Five-year EPS growth rate-8.2%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
One-year change in net income-19.9%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
Returns on capital
7.6%higher is higher, placed against 5,089 companies as of 2026-11-06
Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity7.6%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets3.6%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
29.9%wider is higher, placed against 3,412 companies as of 2026-11-06
Gross margin29.9%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin13.2%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin6.0%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin-8.6%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
16.9xcheaper is higher, placed against 4,362 companies as of 2026-11-06
Price to earnings16.9x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
- Computed from the filing for 2025
Price to book1.3x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio1.0x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
1.22safer is higher, placed against 3,227 companies as of 2026-11-06
Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio1.22
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage4.0x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score2.20
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
2.1%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-06
Dividend yield2.1%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
Payout ratio36.2%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio-3.9x
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.